Research programme: checkpoint inhibitors - OSE Immunotherapeutics

Drug Profile

Research programme: checkpoint inhibitors - OSE Immunotherapeutics

Alternative Names: Effi dem; OSE-172

Latest Information Update: 30 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Effimune
  • Developer OSE Immunotherapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Checkpoint kinase inhibitors; Immunomodulators; SIRPA protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 26 Sep 2017 OSE Immunotherapeutics extends its agreement with Selexis for clinical development of OSE 172
  • 26 Sep 2017 OSE Immunotherapeutics plans to initiate phase I/II clinical trial of OSE 172 in Cancer in 2018
  • 15 Nov 2016 Selexis SA and OSE Immunotherapeutics collaborate to advance preclinical development of OSE 172
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top